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Introduction
The veterinary use of radionuclide techniques dates back to
the mid-sixties [1, 2], but its more extensive use dates back to the
past two decades. In Central and Eastern Europe, it is still in its
infancy with only one large research centre, in Budapest, Hungary.
Veterinary nuclear medicine is focused mainly on four major
issues: bone scintigraphy — with the majority of applications in
horses, veterinary endocrinology — dealing mainly with the pro-
blems of hyperthyreosis in cats and hypothyreosis in dogs, porto-
systemic shunts in small animals and veterinary oncology, how-
ever, most radionuclide techniques applied to humans can be
applied to most animals.
There is little awareness of the usefulness of radionuclide stu-
dies in veterinary practice among the nuclear medicine community.
Therefore, we decided to describe some of its applications.
Clinical applications
Bone scintigraphy
Its main objectives are horses, dogs, and to a lesser extent,
cats. The demand for advanced and correlative imaging methods
in equine medicine is growing. Scintigraphy can provide unique
information about the physiological status of an animal that can-
not be discerned by other imaging modalities. The crucial prob-
lem in horses, where traditional radiographic techniques may not
be sufficient, are leg and neck bone lesions, in the second row
a veterinary oncology.
Orthopaedic applications
Bone scintigraphy offers the major advantage of increased
sensitivity over standard radiographic imaging. Except for consis-
tent identification of bone cysts, most of the pathological chan-
ges to the horse’s musculoskeletal system that might cause lame-
ness can be detected using bone scans. Many acute bone dis-
eases can be diagnosed by scintigraphy that cannot be discerned
by radiographs until the condition has become chronic. Because
of their body size, these conditions may not be diagnosed in horses
at all. Scintigraphy in horses offers the other major advantage
of affording accurate imaging of the upper limbs, pelvis, and ver-
tebral column without general anaesthesia. Therefore, it has the
final advantage of increased safety over conventional radiogra-
phy because it eliminates the need to perform general anaesthe-
sia to study these areas. A second major benefit of scintigraphic
imaging is to differentiate mixed lameness conditions, in which
the component of bone disease must be separated from that of
soft tissue to arrive at a rational course of treatment or prognosis.
Finally, for athletic horses suspected of having lameness due to
localized myositis, scintigraphy not only allows confirmation of
muscle inflammation, but also identifies the injured muscle bellies
reasonably and accurately, so that specific local treatment may
be given. Nuclear imaging of equine skeletal disease is an option
that should be employed more frequently by equine practitioners
for diagnosis of difficult lameness cases. The technique is safe
and comparatively inexpensive when one considers the total ex-
pense of multiple examinations or radiographic surveys of patients
without conclusively diagnosing the source or sources of skeletal
pain. This is particularly true when a horse owner becomes di-
ssatisfied and enlists the services of one or more other veterinar-
ians. The equine specialist will maintain better client rapport if he
or she suggests referral of the horse to a veterinary medical teaching
centre or private clinic where scintigraphic imaging can be car-
ried out, rather than having the client become frustrated and seek
another opinion elsewhere [3].
An important cause of lameness in horses, where scinti-
graphic imaging may be considered, can be stress fractures of
legs [4]. Stress fractures of scapula with positive RN and negative
radiographic imaging also can be met [5].
Lameness detection is also a major problem of, so-called,
veterinary sports medicine, i.e. evaluating the problems of equine
(or canine) athletes. It should be remembered, however, that the
poor performance of animal athletes could be the result not only
of orthopaedic problems, but also of upper and lower airway func-
tion disturbances, which result in increased resistance to airflow
— a major cause of poor racing performance. Scintigraphic im-
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aging modalities can be used to evaluate both global and region-
al lung function in cases of suspected pneumonia, chronic ob-
structive pulmonary disease or emphysema. Nuclear medicine
studies can often offer some help in these situations [6]. In some
cases, bilateral lameness can be the result of aortoiliac thromboem-
bolism, detectable with first-pass radionuclide angiography [7].
Bone scintigraphy may also be used in the detection of occult
lameness in dogs [8]. Scintigraphy has also gained wide accep-
tance in diagnosing elbow dysplasia. The term elbow dysplasia
encompasses a variety of developmental abnormalities that
affect the elbow. Some of the more common conditions referred
to as elbow dysplasia include dissecant osteochondrosis, non-uni-
ted anconeal process, fragmented coronoid process and prema-
ture closure of the ulna. Scintigraphy helps to diagnose joint in-
congruity that has not yet developed into a condition that is de-
tectable by radiography. In addition, scintigraphy has proven help-
ful in localizing lesions in the shoulder, elbow, stifle, and tarsal
joints associated with osteochondrosis and osteoarthritis [9]. In
some cases, radionuclide technique could be used in disorders
secondary to vertebral column lesions; for example there are re-
ports on scintigraphy performed in bulls with decreased libido due
to painful lesions of the vertebral column. Radiographic evalua-
tion of vertebral skeletal problems in mature bulls is limited be-
cause of high body mass. Bone scintigraphy helped to determine
the location of vertebral column lesions and facilitate localized
treatment [10]. Scintigraphy should be considered in all cases of
animal lameness which cannot be diagnosed by conventional
methods.  This technique is also useful as an early indicator of the
disease, not only as a method of ”last hope” [11].
Oncologic bone scintigraphy applications
In veterinary oncology, the principal goal is the detection of
osteosarcoma [12–16]. In limb sarcoma, both radiography and
scintigraphy tend to overestimate its extent when compared with
histopathologic macro-slides of the same lesions. Nuclear scin-
tigraphy overestimates tumour extent to a larger degree than does
radiography. Although radiography is a more accurate method of
measurement of the extent of distal radius osteosarcoma, scinti-
graphy may provide a larger margin of safety for determining the
site of proximal osteotomy during a limb-salvage procedure. How-
ever, caution should be exercised when utilizing scintigraphy,
because this method may overestimate the length of radius in-
volved to such an extent as to cause the surgeon to believe that
a patient is not a suitable limb-salvage candidate [13].
An interesting finding is the extra-skeletal accumulation
of osteotropic radiotracers of osteosarcomas in cats and dogs
[14–16]. This might have some therapeutic importance, as the
therapeutic radiotracers: strontium-89 and samarium-153-EDTMP
were also showed to accumulate in extraosseous sarcomas [17].
The detection of primary and metastatic osteosarcoma has
been also attempted with immunoscintigraphy using F(ab’)2 frag-
ments of osteosarcoma-associated monoclonal antibody TP-1 [18].
Veterinary oncology
Oncophilic agents such as 99m-technetium MIBI and DMSA(V)
have proven to be useful in detecting lymphomas and malignant
schwannomas [19].
As in humans, there is a proven usefulness of sentinel node
detection in oncologic patients [20]. Balogh et al proved the supe-
riority of pre-operative RN sentinel node detection (89%) and intra-
operative radioguided surgery (97%) over blue-dye technique (77%).
Veterinary endocrinology
Most nuclear medicine procedures in this field are related to thy-
roid gland diagnostics and therapy, both in dogs and cats. Hyper-
thyroidism is a crucial problem in cats, and hypothyroidism in dogs.
Feline hyperthyroidism was first described in 1979 and is
a relatively common disease. Its symptoms and signs are, as in
humans, chronic weight loss, intermittent dyspnoea, chronic dia-
rrhoea, hyperactivity and weakness [21]. Diagnosis, as in humans,
is based on palpation, scintigraphy and ultrasound. Management,
again as in humans, is either with thyreostatic agents, surgical or
with radioiodine, and sometimes even with ethanol ablation.
Thyroidal isotope uptake and scintigraphy
Uptake of radioactive iodine (131-I or 123-I) and 99m-tech-
netium as pertechnetate is increased in hyperthyreoidal cats
[22, 23]. Qualitative scintigraphic imaging is a useful procedure
to determine unilateral or bilateral involvement, alterations in the
position of thyroid lobes, the site of hyperfunctioning accessory
or ectopic thyroid tissue, or distant metastases from a functioning
thyroid carcinoma [24]
Radioiodine treatment
Radioiodine therapy of hyperthyroidism in cats is a very im-
portant issue. It is considered to be the safest, simplest and most
effective therapy of feline hyperthyroidism [23].
A target delivery dose to the thyroid is 150 Gy. The average
activity of radioiodine applied varies from 3–5 mCi. It is adminis-
tered orally, intravenously or subcutaneously. The two latter means
of radioiodine administration are preferable, but when compared
with i.v. administration, s.c administration of radioiodine appears
to be safer to personnel, less stressful to the cats and it is current-
ly the preferred route of administration of radioiodine [25]. Oral
administration was attempted, but higher doses are generally re-
quired, the risks of radiation spillage are greater and vomiting may
occur. Euthyroidism may be attained in over 90% of cases with
a single dose ranging from 39 to 222 MBq [23, 27]. Regarding
survival time following treatment of hyperthyroidism with radioio-
dine, 67% of cats were alive and euthyroid up to 33 months after
treatment [29]. Many of the remaining cats died due to renal di-
sease, which could be a side-effect of the treatment (see section
below). Hypothyroidism and recurrent hyperthyroidism can deve-
lop, but seem to be fairly rare; other side effects are minimal [26].
The main drawbacks to widespread use of radioactive iodine
treatment in cats are the requirements for special licensing and
the need of isolation of the cats following treatment, ranging from
a several days to several weeks depending on the dose used and
local radiation regulations.
Radioiodine treatment of hyperthyroidism
in cats — renal disease as a side-effect
Hyperthyroidism itself can mask underlying renal disease [30].
Also the renal function may further be adversely affected by the
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induction of euthyroidism and should be carefully evaluated before
treatment with radioiodine [23]. Renal-irradiation due to radioiodine
renal excretion cannot also be excluded. Renal side-effects care is
also required for treatment with anti-thyroid drugs and surgery.
A significant decline in renal function may frequently occur after the
treatment of hyperthyroidism in cats with previous renal disease,
therefore pre-treatment measurement of GFR is valuable in detec-
ting sub-clinical renal disease and in predicting which cats may have
clinically important declines in renal function following treatment
[30]. In the absence of such estimations, careful evaluation of se-
rum urea and creatinine concentrations and urine specific gravity is
required before radioiodine treatment of hyperthyroidism [23].
Radioiodine treatment of hyperthyroidism
in cats — radioprotection of staff and environment
Just as in humans, a crucial factor is the radioprotection of
staff securing radioiodine-treated cats, due to the radioactivity of
the animals themselves and their urine. The effective decay half-
time after oral administration of 178 to 204 MBq of 131-I (T1/2E)
for surface emissions was 2.19 to 4.70 days, and T1/2E for urine
radioactivity was 2.16 to 3.67 days. Surface gamma-radiation
emission rates for cats following administration of  I-131 appears
useful in determining the upper limits (threshold) of urine radioac-
tivity and are a valid method to assess the time at which cats can
be discharged after I-131 administration [31]. In the USA, it varies
between 3–7 days. In Germany, it requires hospitalization for
approximately two weeks, although the practical considerations
of radiation exposure of cat owners do not justify this long interval
[32]. On the other hand, cats seem to tolerate the period of hospi-
talisation relatively well.
Hypothyroidism
Hypothyroidism is a relatively frequent disorder in dogs.  Un-
derlying causes include thyroid dysgenesis and inherited iodina-
tion defects.  Scintigraphy readily differentiates between those two
conditions because animals with thyroid dysgenesis have mini-
mal uptake of radionuclides in the anatomic region of the thyroid
gland, whereas animals with iodination defects have enlarged thy-
roid lobes with normal or increased tracer uptake [33]. In thyroid
carcinoma and associated hypothyroidism, scintigraphy helps to
localize the lesion, and thus allows adequate planning for surgical
resection and later for post operative evaluation [34]. Radionu-
clide therapy was also reported in animal thyroid carcinoma [35].
Other endocrine disorders
99m-technetium sestamibi may be use for the detection of
a parathyroid adenoma in dogs with primary hyperparathyroidism [36].
Somatostatin receptor scintigraphy using indium In-111 pen-
tatreotide can be performed in APUDoma tumours — this is im-
portant, because these tumours, in dogs, have a poor long-term
prognosis due to a high rate of metastases and recurrence; sta-
ging (and therefore prognosticating) is difficult and usually done
at the time of surgery [37, 38].
Cardiology
Equilibrium gated blood pool study proved to be useful in dogs
with an X-linked, Duchenne-like, muscular dystrophy involving myo-
cardium, the same as human Duchenne muscular dystrophy [39].
Nuclear scintigraphy with 99mTc-MAA proved to be a quick
alternative method to cardiac catheterization in diagnosing right-
-to-left cardiac shunts and quantification of shunt fraction [40].
In peripheral vessels, first-pass radionuclide angiography
proved to be useful in detecting aortoiliac thrombosis [7].
Lungs
Conventional perfusion scintigraphy has the similar indications,
acquisition mode and outcomes as in humans [41].
Ventilation/perfusion scintigraphy in horses provides valuable
additional information on regional lung function that is not obtain-
able from conventional thoracic radiographs. This is particularly
true of horses with chronic obstructive pulmonary disease and
those suspected of having some form of small-airway disease.
Findings from horses with chronic obstructive pulmonary disease
have improved the understanding of the radiographic patterns of
air trapping and vascular distribution, and provided us with a sen-
sitive means of detecting residual bronchial changes in the ab-
sence of clinical signs of the disease. Several other scintigraphic
parameters such as mucociliary clearance and abscess-avid la-
belling show promise for future lung imaging on clinical cases,
but still require further research to develop appropriate techniques
for delivery and image analysis [42].
Gastrointestinal tract and kidneys
GI tract
Probably radionuclide diagnosis of portosystemic shunts
(PSSs) in cats and dogs is most important here.
Portosystemic shunts (PSSs) are abnormal venous commu-
nications allowing blood in the portal system to enter the systemic
venous system directly, without passing the liver. The shunted
blood contains abnormally high levels of compounds absorbed
from the intestinal tract that are normally removed, detoxified or
metabolised by the liver [43]. Shunts are classified as intra- and
extra-hepatic, or, alternatively, as congenital or acquired. Most
feline congenital PSSs consist of a single large vessel represen-
ting a developmental error in which a vascular communication is
maintained between abdominal veins derived from the cardinal
and vitelline veins. Extrahepatic shunts are located outside the liver
parenchyma and most commonly empty into the prehepatic vena
cava. However, some cats may have atypical PSS connections.
The clinical signs in dogs and cats with portosystemic shunts are
highly variable, but usually involve poor growth and central nervous
system signs of postprandial hepato-encephalopathy. These cen-
tral nervous system signs may include intermittent disorientation,
pacing, circling, tremors and even seizures. Congenital shunts are
best managed with surgical intervention, where acquired need
medical treatment. To accomplish this task, veterinarians must be
able to identify patients in which a PSS is a strong possibility.
Transcolonic portal scintigraphy is a non-invasive method of
diagnosing PSS and also allows calculation of the shunt degree,
although scintigraphy, unlike jejunal vein portography, cannot aid
in precise anatomic shunt localization. With a cat under sedation,
99m-technetium (usually as DTPA compound) is placed into the
colon where it is rapidly absorbed into the portal system. In an
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animal with normal portal circulation, the liver field is the first marked
by a radionuclide flow; in PSS, the area represented by a liver is
a void, whereas the heart is the first organ illuminated by the ra-
diotracer flow [43].
Surgical options for PSS occlusion include ligation for acute
vessel occlusion and for slow vessel occlusion using an ameroid
constrictor. The prognosis is based on the degree of shunt occlu-
sion and the ability of the liver to adapt to increased hepatic blood
flow [43]. However, post-operation mortality is high.
The opinions on hepatobiliary scintigraphy with HIDA derivates
are controversial. Whereas some authors advocate this method
in lambs [44], dogs and cats [45], the others say that the method
is insensitive in cholangiohepatic lesions [46]. Quantitative hepa-
tobilliary scintigraphy facilitates the interpretation of the study [47].
Kidneys
In cats and dogs, renal insufficiency is relatively frequent. There
are number of diseases that can affect the kidneys in animals,
which include: infections, neoplasms, cysts, nephrolithiasis, and
injury from toxin exposure (glycol antifreeze, aspirin, acetami-
nophen, ibuprofen), as well as a number of inflammatory diseases
(glomerulonephritis, systemic lupus). Diagnosis of kidney disease
is difficult in the stage of compensation, and impossible when
based solely on routinely performed laboratory tests of blood and
urine. As in humans, only scintigraphy allows unilateral assess-
ment of renal function, which is most important in animals with
morphologically altered kidneys, such as kidney cysts, hydroneph-
rosis or tumours [48]. Quantitative and qualitative scintigraphic
measurement of renal function are presently applied in practice
[49]. Determination of the kidney’s glomerular filtration rate (GFR)
is often taken into account in surgical planning. Only scintigraphy
has the ability to measure individual kidney function. It is of impor-
tance in case of planned surgical nephrotomy or nephrectomy.
As in humans, nuclear medicine techniques may be useful in
evaluating acute renal allograft rejection in dogs and cats, although
there is a debate on superiority of scintigraphic over radiographic
findings in those patients [50].
Infection and inflammation
99mTc-HMPAO-labelled leukocytes scintigraphy is an effec-
tive tool for the diagnosis of orthopaedic infection as a cause of
lameness in horses [51].
99mTc-HMPAO-labelled leukocytes were also used in asse-
ssing small intestinal malabsorption in horses. Intestinal uptake
of activity was detected in 12 of the 17 cases, but in none of the
control horses. The technique was therefore specific for intestinal
pathology, but failed to detect some horses that might have had
intestinal pathology. No indications of the horses’ specific patho-
logy were obtained, and their prognosis or response to treatment
could not be predicted [52].
99mTc-labeled radiopharmaceutical ciprofloxacin can be used
in dogs to reveal the site of an infection [53].
Imaging — miscellanea
Some data might be available from feline hysteroscintigraphy.
These findings demonstrated that fluids or particles deposited in the
vagina of the cat could be transported into the uterus during some
stages of the oestrous cycle. The fluoroscopic and scintigraphic tech-
niques may be further modified to permit more detailed studies of
uterine contractile patterns and sperm transport in the feline female
reproductive tract. The information on cervical patency is also of va-
lue for the development of techniques for artificial insemination in this
species, and should also be studied in the ovulatory cycle [54].
Radionuclide therapy
Radionuclide therapy of hyperthyreosis in cats is reviewed
above. High fixed doses (more than 1000 MBq) were used in cats
after surgical removal of thyroid carcinoma [55].
Bone and joints
153-Sm-EDTMP has been experimentally used in veterinary
medicine for more than a decade to treat bone tumours and to
provide bone pain palliation [56, 57]. Lattimer and co-workers,
after extensive studies in normal dogs [56], applied 153-Sm-EDTMP
in forty dogs with bone tumours [57]. Bone pain palliation occurred
in most cases. Remarkably, there were complete regressions of
some tumours. During the following years, Milner and co-workers
from South Africa [58], and Moe and Aas from Norway applied
153-samarium in treating osteosarcomas [59, 60]. Their results
include the complete regression of tumours in 2 out of 9 treated
dogs. However, in other patients, the palliative effect of radionu-
clide therapy could sparsely be documented.
Radionuclide synovectomy may be applied in horses with good
results, although a “flare” phenomenon may last for up to 72 hours
[61]. In animals, radiosynovectomy using 166-holmium ferric hy-
droxide macro-aggregate or 153-samarium bound to hydroxyap-
atite microspheres and 90-yttrium silicate may be considered as
a supportive therapeutic option for inflamed joints with synovial
lining hyperplasia. It should preferably be used in combination
with pharmacological treatment and/or physical therapy in cases
of osteoarthritis prior to surgery or joint replacement [62].
Ophtalmology
Corneal pannus was shown to respond to radiation therapy
with Sr-90, and long-term benefits can be achieved. Side effects
are minimal. Optimal sequencing of therapy and dosage still has
to be examined [63]. Good results were reported following the
implantation of gold-198 seeds with 65 Gy by local delivery in
cat’s eyelid carcinoma [64].
Radionuclide therapy — varia
Attempts were made to treat essential thrombocytaemia, with
promising results [65].
Staff and equipment
Veterinary dedicated medical equipment dates back to the
eighties [66]. It required a specially constructed gantry, with a head
on a long arm, to enable the imaging of heads and legs in horses.
Today, now that nuclear medicine department are numerous,
either in veterinary hospitals or outpatients practices, there exists
dedicated veterinary PET equipment, with large stationary gan-
tries enabling large animals to be scanned. On some occasions,
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gammacameras originally suited for humans are regenerated and
reconstructed for animal studies either by extension the arm of
the gammacamera’s head or by constructing a special large gan-
try to enable the study of large animals.
Radioprotection of veterinary staff is not a major problem within
the legislated limits for whole body doses, caution should be paid
to secure radioactive waste secondary to urine radionuclide ex-
cretion [67].
Concluding remarks
As shown above, veterinary nuclear medicine is an interesting
entity, covering most fields of interest of radionuclide diagnostics
in humans. Veterinary nuclear medicine is very popular in the USA
and its popularity in Europe is growing. As mentioned in the intro-
duction, in Central Europe it is not very popular, and scientific
activity is in fact limited the to the group of Dr. L. Balogh from
Budapest. This situation should be changed for the benefit of lo-
cal nuclear medicine communities.
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